Recently, Jiang Xinyi’s research group designed an in situ self-assembling hydrogel LDDS (THINRTHINR-CXCL10) based on oligopeptides for the treatment of a postoperative mouse model of GBM (Figure 5) (Zhang H. et al., 2021). This evidence concerns the gene CXCL10 and glioblastoma.